Stock RCKT ROCKET PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-22 pm EDT 		5-day change 1st Jan Change
23.87 USD +4.69% Intraday chart for Rocket Pharmaceuticals, Inc. -0.58% -20.35%
Apr. 16 Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing MT
Apr. 11 Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing
MT
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing
MT
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102
MT
Goldman Sachs Initiates Rocket Pharmaceuticals at Neutral With $39 Price Target
MT
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
BU
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
CI
Rocket Pharmaceuticals Appoints Aaron Ondrey as CFO
MT
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
BU
Rocket Pharmaceuticals, Inc. Announces Appointment of Aaron Ondrey as Chief Financial Officer
CI
Rocket Pharmaceuticals, Inc. Announces Executive Appointments
CI
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?
PR
UBS Adjusts Rocket Pharmaceuticals Price Target to $54 From $56, Maintains Buy Rating
MT
Rocket Pharmaceuticals Q4 Loss Narrows
MT
Rocket Pharmaceuticals: Q4 Earnings Snapshot
AQ
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
BU
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
North American Morning Briefing : S&P 500 Futures -2-
DJ
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I
AQ
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline
MT
FDA Extends Review of Rocket Pharma's Proposed Kresladi
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RCKT Stock
  4. News Rocket Pharmaceuticals, Inc.